Editorial: prevalence, progression rates and mortality predictors of non-alcoholic fatty liver disease reflected by German statutory health insurance data
- PMID: 33105983
- DOI: 10.1111/apt.16077
Editorial: prevalence, progression rates and mortality predictors of non-alcoholic fatty liver disease reflected by German statutory health insurance data
Comment on
-
Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease.Aliment Pharmacol Ther. 2020 Oct;52(7):1185-1194. doi: 10.1111/apt.16016. Epub 2020 Aug 17. Aliment Pharmacol Ther. 2020. PMID: 33016540
References
REFERENCES
-
- Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69:2672-2682.
-
- Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69:896-904.
-
- Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908-922.
-
- Loomba R, Wong R, Fraysse J, et al. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. Aliment Pharmacol Ther. 2020;51:1149-1159.
-
- Canbay A, Kachru N, Haas JS, et al. Patterns and predictors of mortality and disease progression among non-alcoholic fatty liver disease patients in Germany. Aliment Pharmacol Ther 2020;52:1185-1194.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical